p21(ras) in carcinogenesis

被引:14
作者
deVries, JE
tenKate, J
Bosman, FT
机构
[1] DE WEVER HOSP, DEPT CLIN CHEM, HEERLEN, NETHERLANDS
[2] ERASMUS UNIV ROTTERDAM, DEPT PATHOL, NL-3000 DR ROTTERDAM, NETHERLANDS
关键词
apoptosis; p21(ras) on oncogenes; carcinogenesis; cell cycle regulation;
D O I
10.1016/S0344-0338(96)80087-2
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The activation of p21(ras) proteins is required in signal transduction pathways that lead to cell proliferation. More recently, a role for p21(ras) proteins has also been suggested in pathways to apoptosis and in the regulation of the cell cycle. Pointmutated p21(ras) oncogenes code for constitutively activated p21(ras) proteins, which disturb the balance between cell growth and cell growth and cell in favour of cell growth. In this way, p21(ras) oncoproteins may contribute to carcinogenesis. The binding of growth factors to their receptors triggers a cascade of protein interactions, including activation of the p21(ras) proteins. In turn, p21(ras) proteins set the machinery for cell division in motion by stimulating different effector proteins which regulate the morphological alterations, the nutritional requirements, and the changes in gene expression necessary for cell division. The presence of p21(ras) oncoproteins constitutively stimulate proliferation, whilst the apoptotic pathway is suppressed along with the loss of cell cycle regulation. This review describes the function of the p21(ras)proteins in signal transduction pathways that control proliferation and apoptosis, and regulate the cell cycle. The dysregulation of these signal transduction pathways due to the presence of p21(ras) oncoproteins is discussed in the context of early carcinogenesis.
引用
收藏
页码:658 / 668
页数:11
相关论文
共 139 条
[1]   THE ROLE OF JUN, FOS AND THE AP-1 COMPLEX IN CELL-PROLIFERATION AND TRANSFORMATION [J].
ANGEL, P ;
KARIN, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1072 (2-3) :129-157
[2]  
ARENDS MJ, 1994, AM J PATHOL, V144, P1045
[3]   SUSCEPTIBILITY TO APOPTOSIS IS DIFFERENTIALLY REGULATED BY C-MYC AND MUTATED HA-RAS ONCOGENES AND IS ASSOCIATED WITH ENDONUCLEASE AVAILABILITY [J].
ARENDS, MJ ;
MCGREGOR, AH ;
TOFT, NJ ;
BROWN, EJH ;
WYLLIE, AH .
BRITISH JOURNAL OF CANCER, 1993, 68 (06) :1127-1133
[4]   MEMBRANE TARGETING OF THE NUCLEOTIDE EXCHANGE FACTOR SOS IS SUFFICIENT FOR ACTIVATING THE RAS SIGNALING PATHWAY [J].
ARONHEIM, A ;
ENGELBERG, D ;
LI, NX ;
ALALAWI, N ;
SCHLESSINGER, J ;
KARIN, M .
CELL, 1994, 78 (06) :949-961
[5]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[6]   ABERRANT REGULATION OF RAS PROTEINS IN MALIGNANT-TUMOR CELLS FROM TYPE-1 NEUROFIBROMATOSIS PATIENTS [J].
BASU, TN ;
GUTMANN, DH ;
FLETCHER, JA ;
GLOVER, TW ;
COLLINS, FS ;
DOWNWARD, J .
NATURE, 1992, 356 (6371) :713-715
[7]   NEUROFIBROMATOSIS TYPE-1 AND RAS-MEDIATED SIGNALING - FILLING IN THE GAPS [J].
BERNARDS, A .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1995, 1242 (01) :43-59
[8]   PROTEINS REGULATING RAS AND ITS RELATIVES [J].
BOGUSKI, MS ;
MCCORMICK, F .
NATURE, 1993, 366 (6456) :643-654
[9]  
BOS JL, 1989, CANCER RES, V49, P4682
[10]  
BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0